Research
Hormonal
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, sotagliflozin) significantly reduce major adverse cardiovascular events (MACE-3), cardiovascular death, and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.
If you have Type 2 Diabetes and heart disease or heart failure, SGLT2 inhibitors are a first-line treatment option that protects your heart and reduces hospitalization risk, regardless of your blood sugar levels. Consult your doctor about these specific medications.
StrongSupportsVERY_HIGH confidence
The three classes of drugs that have been most extensively studied are ... sodium-glucose cotransporter-2 (SGLT2) inhibitors, the latter two reporting significant reductions in adverse cardiovascular outcomes independent of their glycemic effect.
Why this rating
Based on multiple large-scale, randomized controlled trials (EMPA-REG, CANVAS, DAPA-HF, etc.) with consistent positive outcomes.
Source
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
Khawaja M. Talha et al. · Methodist DeBakey Cardiovascular Journal · 2022
DOI 10.14797/mdcvj.1155
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (Liraglutide, Semaglutide, Dulaglutide, Albiglutide, Efpeglenatide) significantly reduce MACE-3 and cardiovascular death in patients with Type 2 Diabetes and high cardiovascular risk.Strong
- SGLT2 inhibitors significantly reduce heart failure hospitalizations and cardiovascular death in patients with Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF), regardless of diabetes status.Strong
- DPP-4 inhibitors (Sitagliptin, Saxagliptin, Alogliptin, Linagliptin) are generally neutral for cardiovascular outcomes, with specific agents (Saxagliptin, Alogliptin) associated with an increased risk of heart failure hospitalization.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →